Search results for "CV"

showing 10 items of 904 documents

Correlation between work impairment, scores of rhinitis severity and asthma using the MASK-air ® App

2020

Background: In allergic rhinitis, a relevant outcome providing information on the effectiveness of interventions is needed. In MASK-air (Mobile Airways Sentinel Network), a visual analogue scale (VAS) for work is used as a relevant outcome. This study aimed to assess the performance of the work VAS work by comparing VAS work with other VAS measurements and symptom-medication scores obtained concurrently. Methods: All consecutive MASK-air users in 23 countries from 1 June 2016 to 31 October 2018 were included (14 189 users; 205 904 days). Geolocalized users self-assessed daily symptom control using the touchscreen functionality on their smart phone to click on VAS scores (ranging from 0 to 1…

0301 basic medicineSYMPTOMSSmart phoneAllergyEscala visual analógicaINNOVATION[SDV]Life Sciences [q-bio]Medical and Health SciencesCorrelationvisual analogue scale0302 clinical medicineQuality of lifeVisual analogue scaleQUALITY-OF-LIFEMàscaresImmunology and AllergyscoreNoseRinitisRhinitisPRODUCTIVITY COSTSasthma; MASK; rhinitis; score; visual analogue scaleScoreExplained variationResponse VariabilityMobile ApplicationsALLERGIC RHINITISrhinitimedicine.anatomical_structureTRIALSRinite1107 Immunology[SDV.IMM]Life Sciences [q-bio]/ImmunologySmartphonemedicine.medical_specialtyMASKVisual analogue scaleMASK study groupImmunologyMACVIA-ARIA03 medical and health sciencesAllergicrhinitismedicineHumansvisual analogue scale.TECHNOLOGYIMMUNOTHERAPYAsmaAsthmabusiness.industryasthma; MASK; rhinitis; score; visual analogue scale; Humans; Smartphone; Asthma; Mobile Applications; Rhinitis; Rhinitis Allergicasthmamedicine.diseaseRhinitis AllergicAsthmaRHINOCONJUNCTIVITIS030104 developmental biology030228 respiratory system3121 General medicine internal medicine and other clinical medicinePhysical therapyClinical Medicinebusiness[SDV.MHEP]Life Sciences [q-bio]/Human health and pathology
researchProduct

Diagnostic and Prognostic Relevance of Red Blood Cell Distribution Width for Vascular Aging and Cardiovascular Diseases.

2019

Evidence suggests association of red blood cell distribution width (RDW) with cardiovascular diseases (CVDs). On the contrary, we underline that the sole RDW values cannot represent a valid CVD biomarker. High RDW values are expression of biological effects of a lot of both endogenous and exogenous factors (i.e., age, sex, genetic background, inflammation, hormones, drugs, diet, exercise, hematological analyzers, and ranges of values), modulating the biology and physiology of erythrocytes. Thus, the singular monitoring of RDW cannot be used to predict cardiovascular disorders. Accordingly, we have reviewed the evidence for potential relationship of RDW values with alterations in the cardiov…

0301 basic medicineSenescenceErythrocyte Indicescirculating endothelial progenitor cells and nucleated red blood cellAgingleukocyte telomere lengthsInflammationDiseaseBioinformaticsEpigenesis Geneticleukocyte telomere length03 medical and health sciencesCVDs; RDW; circulating endothelial progenitor cells and nucleated red blood cells; leukocyte telomere lengths; vascular aging; Aging; Biomarkers; Cardiovascular Diseases; Epigenesis Genetic; Humans; Prognosis; Erythrocyte Indices0302 clinical medicineGeneticmedicineRDW; CVDs; vascular ageing; leukocyte telomere lengths; circulating endothelial progenitor cells and nucleated red blood cells.Settore MED/05 - Patologia ClinicaRDWHumansCVDsProgenitor cellvascular ageingbusiness.industryNucleated Red Blood CellRed blood cell distribution widthCVDPrognosisSettore MED/23030104 developmental biologyvascular agingCardiovascular DiseasesBiomarker (medicine)Geriatrics and Gerontologymedicine.symptombusiness030217 neurology & neurosurgerycirculating endothelial progenitor cells and nucleated red blood cellsBiomarkersHormoneEpigenesisRejuvenation research
researchProduct

Molecular Characterization of Coxsackievirus B5 Isolates from Sewage, Italy 2016–2017

2019

Hereby, the partial Viral Protein 1 sequences of Coxsackievirus B5 (CV-B5) from sewage samples, collected in Italy from 2016 to 2017, were compared with those available in GenBank from clinical samples. Phylogenetic analysis highlighted: (I) the predominant circulation of CV-B5 genogroup B in Italy, and (II) the presence of two new sub-genogroups.

0301 basic medicineSettore MED/07 - Microbiologia E Microbiologia ClinicaEpidemiologyViral proteinHealth Toxicology and Mutagenesisviruses030106 microbiologySewage010501 environmental sciencesBiologyCoxsackievirusmedicine.disease_causeBrief Communication01 natural sciences03 medical and health sciencesViral ProteinsPhylogenetic analysiNon-polio enterovirusePhylogeneticsVirologymedicineCoxsackievirusPhylogeny0105 earth and related environmental sciencesPoliovirusePhylogenetic analysisCV-B5Phylogenetic treeSewagebusiness.industryvirus diseasesNon-polio enterovirusesbiology.organism_classificationVirologyEnterovirus B HumanItalyGenBankPoliovirusesCoxsackievirubusinessFood ScienceEnvironmental Monitoring
researchProduct

GSK-3 in liver diseases: Friend or foe?

2020

Liver diseases, including hepatitis due to hepatitis B or C virus infection, non-alcoholic fatty liver disease, and hepatocellular carcinoma pose major challenges for overall health due to limited curative treatment options. Thus, there is an urgent need to develop new therapeutic strategies for the treatment of these diseases. A better understanding of the signaling pathways involved in the pathogenesis of liver diseases can help to improve the efficacy of emerging therapies, mainly based on pharmacological approaches, which influence one or more specific molecules involved in key signal transduction pathways. These emerging therapies are very promising for the prevention and treatment of …

0301 basic medicineSignaling pathwaysDruggabilityDiseaseBioinformaticsNon-alcoholic fatty liver disease (NAFLD)Glycogen Synthase Kinase 303 medical and health sciences0302 clinical medicineGSK-3Glycogen synthase kinase 3 (GSK-3)AnimalsHumansMedicineHepatitis B virus (HBV)Molecular Targeted TherapyEnzyme InhibitorsHepatocellular carcinoma (HCC)Molecular BiologyHepatitisbusiness.industryLiver DiseasesFatty liverDisease ManagementHepatitis C virus (HCV)Cell BiologyHepatitis Bmedicine.disease030104 developmental biologyGene Expression RegulationMultigene Family030220 oncology & carcinogenesisHepatocellular carcinomaHost-Pathogen InteractionsDisease SusceptibilitySignal transductionbusinessBiomarkersSignal TransductionBiochimica et Biophysica Acta (BBA) - Molecular Cell Research
researchProduct

Daclatasvir-based regimens in HCV cirrhosis: experience from the Italian early access program

2019

AbstractWe reported the efficacy and safety data for daclatasvir (DCV)-based all-oral antiviral therapy in patients treated in the Italian compassionate-use program. 275 patients were included (202 male-73.5%, mean age: 57.4 years, 62 HIV-coinfected, 94 with recurrence of hepatitis C post-OLT). Forty-nine patients (17.8%) had Child-Pugh B, Genotype(G) distribution was: G1a:72 patients (26.2%), G1b:137 (49.8%); G3:40 (14.5%) and G4:26 (9.5%). Patients received DCV with sofosbuvir(SOF) (n = 221, 129 with ribavirin(RBV) or with simeprevir (SMV) or asunaprevir (ASU) (n = 54, 19 with RBV) for up to 24 weeks. Logistic regression was used to identify baseline characteristics associated with sustai…

0301 basic medicineSimeprevirLiver CirrhosisMalePyrrolidinesSofosbuvirSustained Virologic Responselcsh:MedicineSettore MED/05Gastroenterologychemistry.chemical_compound0302 clinical medicineLiver Function TestsINFECTIONMedicinePLUS SOFOSBUVIRlcsh:ScienceSulfonamidesMultidisciplinaryImidazolesValineHepatitis CMiddle AgedTreatment OutcomeItalySAFETYHCVSUSTAINED VIROLOGICAL RESPONSEDrug Therapy CombinationFemaleRIBAVIRINSettore BIO/19 - MICROBIOLOGIA GENERALECHRONIC HEPATITIS-Cmedicine.drugAdultmedicine.medical_specialtyDaclatasvirDrug-Related Side Effects and Adverse ReactionsAntiviral AgentsArticle03 medical and health sciencesInternal medicineHumansAgedADVANCED LIVER-DISEASEbusiness.industryRibavirinVIRUS GENOTYPE 3lcsh:RHepatitis C ChronicHCV HIV Daclatasvirmedicine.diseaseIsoquinolinesEFFICACYRegimen030104 developmental biologychemistryAsunaprevirlcsh:QLiver functionCarbamatesSofosbuvirbusiness030217 neurology & neurosurgeryScientific Reports
researchProduct

Effects of muscular dystrophy, exercise and blocking activin receptor IIB ligands on the unfolded protein response and oxidative stress

2016

Protein homeostasis in cells, proteostasis, is maintained through several integrated processes and pathways and its dysregulation may mediate pathology in many diseases including Duchenne muscular dystrophy (DMD). Oxidative stress, heat shock proteins, endoplasmic reticulum (ER) stress and its response, i.e. unfolded protein response (UPR), play key roles in proteostasis but their involvement in the pathology of DMD are largely unknown. Moreover, exercise and activin receptor IIB blocking are two strategies that may be beneficial to DMD muscle, but studies to examine their effects on these proteostasis pathways are lacking. Therefore, these pathways were examined in the muscle of mdx mice, …

0301 basic medicineX-Box Binding Protein 1Activin Receptors Type IIEukaryotic Initiation Factor-2MyostatinUPRBiochemistryMiceeIF-2 KinaseThioredoxinsSirtuin 1ENDOPLASMIC-RETICULUM STRESSDISULFIDE-ISOMERASEPhosphorylationta315Endoplasmic Reticulum Chaperone BiPHeat-Shock ProteinsIN-VIVOta3141Activin receptorMOUSE MODELER STRESSEndoplasmic Reticulum Stress3. Good healthmedicine.anatomical_structuremyostatinPRESERVES MUSCLE FUNCTIONER-stressSKELETAL-MUSCLEmdxSignal TransductionEXPRESSIONmedicine.medical_specialtyXBP1MDX MICEBiologyProtein Serine-Threonine Kinases03 medical and health sciencesPhysiology (medical)Internal medicineHeat shock proteinPhysical Conditioning AnimalEndoribonucleasesmedicineAnimalsHumansRNA MessengerMuscle SkeletalSkeletal muscleMyostatinGENEActivating Transcription Factor 6Immunoglobulin Fc FragmentsMuscular Dystrophy DuchenneDisease Models Animal030104 developmental biologyProteostasisEndocrinologyGene Expression RegulationUnfolded protein responsebiology.proteinMice Inbred mdxProteostasisUnfolded Protein Response3111 BiomedicineCarrier ProteinsACVR2B
researchProduct

2018

Background Cancer cachexia increases morbidity and mortality, and blocking of activin receptor ligands has improved survival in experimental cancer. However, the underlying mechanisms have not yet been fully uncovered. Methods The effects of blocking activin receptor type 2 (ACVR2) ligands on both muscle and non-muscle tissues were investigated in a preclinical model of cancer cachexia using a recombinant soluble ACVR2B (sACVR2B-Fc). Treatment with sACVR2B-Fc was applied either only before the tumour formation or with continued treatment both before and after tumour formation. The potential roles of muscle and non-muscle tissues in cancer cachexia were investigated in order to understand th…

0301 basic medicinebiologybusiness.industrySkeletal muscleMyostatinActivin receptormedicine.disease3. Good healthCachexia03 medical and health sciences030104 developmental biologymedicine.anatomical_structurePhysiology (medical)biology.proteinCancer researchRespiratory muscleMedicineOrthopedics and Sports MedicinebusinessMechanistic target of rapamycinPI3K/AKT/mTOR pathwayACVR2BJournal of Cachexia, Sarcopenia and Muscle
researchProduct

Optimized production and purification of Coxsackievirus B1 vaccine and its preclinical evaluation in a mouse model.

2017

Coxsackie B viruses are among the most common enteroviruses, causing a wide range of diseases. Recent studies have also suggested that they may contribute to the development of type 1 diabetes. Vaccination would provide an effective way to prevent CVB infections, and the objective of this study was to develop an efficient vaccine production protocol for the generation of novel CVB vaccines. Various steps in the production of a formalin-inactivated Coxsackievirus B1 (CVB1) vaccine were optimized including the Multiplicity Of Infection (MOI) used for virus amplification, virus cultivation time, type of cell growth medium, virus purification method and formulation of the purified virus. Safety…

0301 basic medicineformalin inactivationviruksetvirusesDrug Evaluation PreclinicalPolysorbatesmedicine.disease_causeAntibodies ViralMice0302 clinical medicineMultiplicity of infectionImmunogenicity VaccinevaccineChlorocebus aethiops030212 general & internal medicineImmunogenicityVaccinationVaccinationInfectious Diseasescoxsackievirus B1Molecular MedicineFemaleUltracentrifugeVirus CultivationCoxsackievirus InfectionsBiologyCoxsackievirusta3111VirusMicrobiology03 medical and health sciencesFormaldehydemedicineAnimalsCVB1Vero CellscoxsackievirusGeneral VeterinaryGeneral Immunology and Microbiologyrokotteetta1182Public Health Environmental and Occupational HealthViral Vaccinesbiology.organism_classificationVirologyAntibodies NeutralizingVirus CultivationEnterovirus A HumanDisease Models Animal030104 developmental biologyVaccines Inactivatedvirus purificationEnterovirusVaccine
researchProduct

Real life experiences in HCV management in 2018

2019

Introduction: Hepatitis C virus (HCV) infection is a major cause of chronic liver disease, with approximately 71 million chronically infected individuals worldwide. Treatment of chronic hepatitis C has considerably improved in the last few years thanks to the introduction of direct-acting antivirals able to achieve sustained virological response in more than 95% of patients. Successful anti-HCV treatment can halt liver disease progression and solve the HCV-related extra-hepatic manifestations, eventually reducing liver-related and overall mortality. Areas covered: With the aim to respond to unmet needs in patient’s identification, universal access to antiviral therapy and treatment optimiza…

0301 basic medicinehepatitis C virusSofosbuvirSustained Virologic ResponseAntiviral therapyAntiviral therapy; chronic liver disease; DAAs; HCV; hepatitis C virus; Microbiology; Microbiology (medical); Infectious Diseases; Virologymedicine.disease_causeChronic liver diseaseHealth Services Accessibility0302 clinical medicinedirect acting antiviralshepatitis C viruMass Screening030212 general & internal medicineChronicComputingMilieux_MISCELLANEOUSHepatitis CHepatitis BHepatitis CPibrentasvirAntiviral therapy; chronic liver disease; DAAs; HCV; hepatitis C virus; Antiviral Agents; Disease Progression; Health Services Accessibility; Hepatitis C Chronic; Humans; Italy; Mass Screening; Sustained Virologic ResponseInfectious DiseasesItalyHCVDisease ProgressionAntiviral therapy; chronic liver disease; DAAs; HCV; hepatitis C virus; Antiviral Agents; Disease Progression; Health Services Accessibility; Hepatitis C; Chronic; Humans; Italy; Mass Screening; Sustained Virologic Responsemedicine.drugHumanMicrobiology (medical)Settore MED/17 - Malattie InfettiveHepatitis C virus030106 microbiologyInfectious DiseaseAntiviral AgentsMicrobiology03 medical and health sciencesVirologymedicineHumansAntiviral therapy; DAAs; HCV; chronic liver disease; direct acting antivirals; hepatitis C virusMass screeningDAAHepatitis B virusAntiviral Agentbusiness.industrychronic liver diseaseDAAsHepatitis C Chronicmedicine.diseaseVirologybusiness
researchProduct

Association of immunoglobulin GM allotypes with longevity in long-living individuals from Southern Italy

2018

Abstract Background The aim of this study was to analyse the role of GM allotypes, i.e. the hereditary antigenic determinants expressed on immunoglobulin polypeptide chains, in the attainment of longevity. The role played by immunoglobulin allotypes in the control of immune responses is well known as well as the role of an efficient immune response in longevity achievement. So, it is conceivable that particular GM allotypes may contribute to the generation of an efficient immune response that supports successful ageing, hence longevity. Methods In order to show if GM allotypes play a role in the achievement of longevity, we typed the DNA of 95 Long-living individuals (LLIs) and 96 young con…

0301 basic medicinelcsh:Immunologic diseases. AllergyAgingImmunoglobulin Allotypesmedia_common.quotation_subjectLongevityImmunologyLocus (genetics)Biologylcsh:Geriatrics03 medical and health sciences0302 clinical medicineGenotypeGM allotypes; HMCV; HSV-1; Immune response; Longevity; Immunology; AgingAlleleImmune responseAllele frequencymedia_commonGeneticsGM allotypeSettore MED/04 - Patologia GeneraleResearchLongevityHSV-1Allotypelcsh:RC952-954.6030104 developmental biologyHMCVbiology.proteinGM allotypesAntibodylcsh:RC581-607030215 immunology
researchProduct